Apicomplexa, trypanosoma and parasitic nematode protein kinases as antiparasitic therapeutic targets

Fina Liotta, John J. Siekierka

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Parasitic infections caused by Plasmodium, Trypanosoma, Leishmania, Toxoplasma and parasitic nematodes affect hundreds of millions of individuals worldwide and are the cause of significant mortality and morbidity, particularly in developing countries. These diseases also have an impact on individuals from developed countries; for example, some US troops in Iraq and Afghanistan have been infected with Leishmania. The annual mortality associated with parasitic infections is estimated to be 1.5 million deaths. The socioeconomic impact of the morbidity associated with parasitic infections is significant, and the development of new drugs, aimed at novel targets, is urgently needed to develop effective treatments for these diseases. The small-molecule inhibitors discussed in this review constitute useful tools with which to explore the relevance of kinase inhibition in inducing antiparasitic activity. The aim of recent target-based approaches used in the development of parasite kinase inhibitors is to identify novel antiparasitic agents with therapeutic potential.

Original languageEnglish
Pages (from-to)147-156
Number of pages10
JournalCurrent Opinion in Investigational Drugs
Issue number2
StatePublished - Feb 2010


  • Helminthic disease
  • Leishmaniasis
  • Protein kinase
  • Synthetic inhibitor
  • Toxoplasma
  • Trypanosomiasis


Dive into the research topics of 'Apicomplexa, trypanosoma and parasitic nematode protein kinases as antiparasitic therapeutic targets'. Together they form a unique fingerprint.

Cite this